Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03405337 · ClinicalTrials.gov registry record
Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 160
- Enrollment target
NCT03405337 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 160 participants.
The verdict
NCT03405337 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
Study Summary
This US study will assess hemophilia A patient characteristics, health history and reasons for switching or not switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A: 1) patients who have switched from conventional therapy to new FVIII products with an improved PK profile. 2) patients who remain on conventional therapy (who have never switched) but have considered switching, including those patients who switched from conventional therapy to new FVIII products with improved pharmacokinetics and then subsequently "switched back" to conventional replacement therapy. In doing so, real world evidence will be obtained from both patient and physician perspectives offering key insights for effective therapeutic management of patients with hemophilia A and to more fully understand what drives patient switching from a patient perspective and a physician perspective.
Interventions
- DRUG FVIII products
- DRUG Conventional FVIII replacement therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2018-06-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03405337
The ClinicalTrials.gov registry entry for NCT03405337 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FVIII products is the first listed.
NCT03405337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03405337 about?
NCT03405337 is a clinical study titled "Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies". This US study will assess hemophilia A patient characteristics, health history and reasons for switching or not switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A: 1) patients who have switched from conventional therapy t...
What is the current status of trial NCT03405337?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2018-02-14. Estimated completion is 2018-06-13.
What interventions are being tested in trial NCT03405337?
The interventions under investigation include: FVIII products (DRUG), Conventional FVIII replacement therapies (DRUG).
Who is sponsoring clinical trial NCT03405337?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.